Timothy D. Shafman
MD
Radiation Oncologist
Languages spoken
English
Expert in
Lung cancer, Brain tumors, Breast cancer
Overview
Centers
Specializes in
Treatments
Timothy D. Shafman, MD graduated with honors from Harvard Medical School and spent the first ten years of his career conducting research on cancer-related issues and caring for patients with brain tumors and lung cancer. Dr. Shafman joined the GenesisCare Oncology team in June of 2004 is the Medical Director of our Rhode Island and Massachusetts regional networks. He now serves as the US CMO of Radiation Oncology and Quality & Safety for GenesisCare. He has published over 50 peer-reviewed articles on a range of topics including lung cancer, brain tumors, breast cancer and the genetics of radiation sensitivity.
.svg){kind=icon}
Career positions
- US CMO, Radiation Oncology and Quality & Safety, GenesisCare US
- Assistant Professor, Harvard Medical School, Department of Radiation Oncology
- Assistant Professor, Duke University Medical School, Department of Radiation Oncology
- SVP, National Medical Director, 21st Century Oncology
Education
Universities
- Brandeis University, Bachelor of Arts, Waltham, MA
- Harvard Medical School Massachusetts Institute of Technology, Health Science & Technology, Medical Degree, Cum Laude, Boston, MA
Residencies
- Harvard Medical School Joint Center for Radiation Therapy, Radiation Oncology, Chief Resident, Boston, MA
Internships
- Brigham & Women’s Hospital, Internal Medicine, Boston, MA
Professional associations
Accomplishments
Publications
- Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
- Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
- Patient-reported quality of life after stereotactic body radiation therapy vs. moderate hypofractionation for clinically localized prostate
- Patient-reported quality of life after stereotactic body radiation therapy vs. moderate hypofractionation for clinically localized prostate
- A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
- Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. View publication
Presentations
Z091420165
Johnson SB, Soulos PR, Shafman TD, Mantz CA, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB, 2016, ASTRO
Z091420164
Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein S, Shafman TD, Husain ZA, Evans SB, Yu JB, Gross CP, Decker RH, 2016, ASTRO
Z091420163
Hong J, Gross CP, Shafman T, Hu X, Yu J, Ross R, Finkelstein S, Park H, Soulos P, Evans S., 2016, ASTRO
Z091420162
Finkelstein SE, Forman J, Fernandez E, Chen C, Lieberfarb M, Salenius SA, Shafman T, and Mantz CA, 2016, ASTRO
Z080120161
Alfred Tinger MD, Elizabeth Chabner MD, Sharon Salenius MPH, Evelyn Staviski RTT, Neil Beitch RTT, CMD, Ulrich Hermanto, MD, John Del Rowe MD, Timothy Shafman MD, 2016, RSNA